Commentary on the article “Safety of first line therapy drugs in multiple sclerosis in terms of pregnancy” Commentary

Main Article Content

Agnieszka Piechal

Abstract

None

Article Details

Section
Articles

References

1. Drew P.D., Chavis J.A.: Female sex steroids: effects upon microglial cell activation. J. Neuroimmunol. 2000; 111: 77-85.
2. Ponsonby A.L., Lucas R.M., van der Mei I.A. et al.: Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 2012; 78: 867-874.
3. Vukusic S., Hutchinson M., Hours M. et al.: Pregnancy and multiple sclerosis (The PRIMS Study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353-1360.
4. Hellwig K., Beste C., Brune N. et al.: Increased MS relapse rate during assisted reproduction technique. J. Neurol. 2008; 255(4): 592-593.
5. Tsang B.: MS: diagnosis, management and prognosis. Aust. Fam. Phys. 2011; 40: 948-955.
6. Houtchens M.K., Lublin F.D., Miller A.E., Knoury S.J.: Multiple sclerosis and other inflammatory demyelinating disease of the central nervous system. W: Daroff R.B., Fenichel G.M., Jankovic J., Mazziotta J.C. (red.): Bradley’s Neurology in Clinical Practice. Wyd. 6. Elsevier, Philadelphia 2012: 1283-1313.